Guidelines for the Management of Cholestatic Liver Diseases (2021)

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2022 Sep 5

PMID 36062287

Authors

Lungen Lu

Affiliations

Soon will be listed here.

Abstract

In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology issued a consensus statement on the diagnosis and management of cholestatic liver diseases. More clinical data on this topic have appeared during recent years. The Autoimmune Liver Disease Group of the Chinese Society of Hepatology organized an expert group to review recent evidence and provide an update to these previous guidelines. Herein, we provide 22 recommendations as a working reference for the management of cholestatic liver diseases by clinical practitioners.

Citing Articles

Efficacy and Safety of Ileal Bile Acid Transport Inhibitors in Inherited Cholestatic Liver Disorders: A Meta-analysis of Randomized Controlled Trials.

Imran M, Elsnhory A, Ibrahim A, Elnaggar M, Tariq M, Mehmood A J Clin Exp Hepatol. 2025; 15(3):102462.

PMID: 39802553 PMC: 11720443. DOI: 10.1016/j.jceh.2024.102462.

Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.

Savino A, Rossi A, Fagiuoli S, Invernizzi P, Gerussi A, Vigano M Cancers (Basel). 2025; 17(1.

PMID: 39796705 PMC: 11718971. DOI: 10.3390/cancers17010076.

Prolonged Direct Hyperbilirubinemia Following Acute Hepatitis: When Not to Worry?.

Zhao D, Wu G J Clin Transl Hepatol. 2024; 12(12):985-987.

PMID: 39649028 PMC: 11622201. DOI: 10.14218/JCTH.2024.00265.

Atypical Cases of Leptospirosis: Insights From Georgia.

Dehkordi A, Al-Tamary S, Al-Tamary A, Al-Tamary H, Albarari S, Assad A Case Rep Infect Dis. 2024; 2024:1414417.

PMID: 39610672 PMC: 11602529. DOI: 10.1155/2024/1414417.

The non-HDL-C to APOB ratio as a predictor of inaccurate LDL-C measurement in patients with chronic intrahepatic cholestasis and jaundice: a retrospective study.

Cheng Y, Ye J, Huang J, Wang Y PeerJ. 2024; 12:e18224.

PMID: 39376224 PMC: 11457871. DOI: 10.7717/peerj.18224.

References

Zhang J, Liu L, Gong J, Hao C, Qiu Y, Lu Y . TJP2 hepatobiliary disorders: Novel variants and clinical diversity. Hum Mutat. 2019; 41(2):502-511. DOI: 10.1002/humu.23947. View

Vitale G, Gitto S, Vukotic R, Raimondi F, Andreone P . Familial intrahepatic cholestasis: New and wide perspectives. Dig Liver Dis. 2019; 51(7):922-933. DOI: 10.1016/j.dld.2019.04.013. View

. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2018; 70(1):172-193. PMC: 6657019. DOI: 10.1016/j.jhep.2018.06.024. View

Cao X, Gao Y, Zhang W, Xu P, Fu Q, Chen C . [Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai]. Zhonghua Gan Zang Bing Za Zhi. 2015; 23(8):569-73. DOI: 10.3760/cma.j.issn.1007-3418.2015.08.003. View

Smith D, Rood K . Intrahepatic Cholestasis of Pregnancy. Clin Obstet Gynecol. 2019; 63(1):134-151. DOI: 10.1097/GRF.0000000000000495. View

Hilscher M, Kamath P, Eaton J . Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. Mayo Clin Proc. 2020; 95(10):2263-2279. DOI: 10.1016/j.mayocp.2020.01.015. View

Thebaut A, Habes D, Gottrand F, Rivet C, Cohen J, Debray D . Sertraline as an Additional Treatment for Cholestatic Pruritus in Children. J Pediatr Gastroenterol Nutr. 2016; 64(3):431-435. DOI: 10.1097/MPG.0000000000001385. View

Phaw N, Leighton J, Dyson J, Jones D . Managing cognitive symptoms and fatigue in cholestatic liver disease. Expert Rev Gastroenterol Hepatol. 2020; 15(3):235-241. DOI: 10.1080/17474124.2021.1844565. View

Staufer K . Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci. 2020; 21(22). PMC: 7696864. DOI: 10.3390/ijms21228586. View

10.

Shneider B, Spino C, Kamath B, Magee J, Bass L, Setchell K . Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome. Hepatol Commun. 2018; 2(10):1184-1198. PMC: 6167076. DOI: 10.1002/hep4.1244. View

11.

Reichert M, Hall R, Krawczyk M, Lammert F . Genetic determinants of cholangiopathies: Molecular and systems genetics. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1484-1490. DOI: 10.1016/j.bbadis.2017.07.029. View

12.

Li L, Li Z, Yang Y, Lu Y, Xie X, Chen L . ABCB11 deficiency presenting as transient neonatal cholestasis: Correlation with genotypes and BSEP expression. Liver Int. 2020; 40(11):2788-2796. DOI: 10.1111/liv.14642. View

13.

Dubrovsky A, Bowlus C . Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases. Gastroenterol Hepatol (N Y). 2021; 16(1):31-38. PMC: 8040906. View

14.

Floreani A, Gervasi M . New Insights on Intrahepatic Cholestasis of Pregnancy. Clin Liver Dis. 2015; 20(1):177-89. DOI: 10.1016/j.cld.2015.08.010. View

15.

Boelle P, Debray D, Guillot L, Clement A, Corvol H . Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology. 2018; 69(4):1648-1656. PMC: 6519059. DOI: 10.1002/hep.30148. View

16.

Pan Q, Luo G, Qu J, Chen S, Zhang X, Zhao N . A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis. EMBO Mol Med. 2021; 13(11):e14563. PMC: 8573601. DOI: 10.15252/emmm.202114563. View

17.

. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View

18.

Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D . Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021; 398(10311):1581-1592. DOI: 10.1016/S0140-6736(21)01256-3. View

19.

Emerick K, Rand E, Goldmuntz E, Krantz I, Spinner N, Piccoli D . Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999; 29(3):822-9. DOI: 10.1002/hep.510290331. View

20.

Wagner M, Fickert P . Drug Therapies for Chronic Cholestatic Liver Diseases. Annu Rev Pharmacol Toxicol. 2019; 60:503-527. DOI: 10.1146/annurev-pharmtox-010818-021059. View